Puma Biotechnology Inc., of Los Angeles, is commencing an underwritten public offering of $150 million of shares of its common stock. Puma intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock. Citigroup and J.P. Morgan are acting as lead book-running managers for the offering.